Navigation Links
Synthetic Biologics Completes $10.8 Million Private Placement Financing
Date:10/31/2012

ROCKVILLE, Md., Oct. 31, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, announced today the successful completion of its previously announced private placement in connection with stock purchase agreements dated October 25, 2012. The Company sold approximately 6.8 million shares of its common stock at a purchase price of $1.60 per share to new and existing investors for gross proceeds of approximately $10.8 million. This transaction was completed at a discount to market and no warrants were issued to the investors. Existing investors and an affiliate of R.J. Kirk constituted a majority of the participating investors in this transaction.

"We are very pleased to complete this financing and to receive such solid support from both our new and existing investors, who share our vision of the emerging field of synthetic biologics," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, Inc. "This new capital provides us with a strong cash position going forward. It allows us to advance our lead programs to develop monoclonal antibody therapies for certain infectious diseases and a synthetic DNA-based therapy for pulmonary arterial hypertension through our Exclusive Channel Collaborations with Intrexon Corporation. We believe that we are well-positioned to achieve significant milestones related to these cutting edge development programs."

In addition to funding the Company's monoclonal antibody and synthetic DNA programs, the net proceeds are intended to be used for general corporate purposes, including the execution of its business plan as well as the expansion and advancement of its pipeline.

The common stock sold in the private placement transaction has not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws and was issued and sold in
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Synthetic Biologics Announces $10.8 Million Financing
2. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
3. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
4. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
5. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
6. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
7. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
10. Adeona Becomes Synthetic Biologics, Inc.
11. Startling results in synthetic chemistry presented in Nature Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... 2013  Empire Genomics announced today it has ... novel genomic biomarker from Cornell University for use ... help in diagnosing and determining treatment for patients ... Neuroendocrine prostate cancer (NEPC) is a lethal variant ... novo, but more commonly arises after hormonal therapy ...
(Date:5/22/2013)... CANTON, Mass. and NEW ORLEANS ... commercial leader in the field of regenerative medicine, presented ... expert economists from Analysis Group (a leading health economics ... that diabetic foot ulcers (DFU) and venous leg ulcers ... The results of this research, which reveal annual ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... 4, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... a conference call and live audio webcast on Thursday, May ... update and discuss its first quarter 2011 financial results.   ... (domestic) or 1-617-597-5328 (international) and reference access code 64874944. ...
... Researchers at the Institute for Genome Sciences at the ... the FBI, the U.S. Army Medical Research Institute of ... first scientific paper based on their investigation into the ... its use of genomics and microbiology in a criminal ...
... to develop a new drug that will regenerate a ... a person is exposed to deadly chemical warfare agents. ... Ohio State University (OSU), is leveraging Ohio Supercomputer Center ... to lethal chemicals called organophosphorus (OP) nerve agents. ...
Cached Biology Technology:Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4OSU chemist developing solution to nerve agent exposure 2
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
(Date:5/23/2013)... MADISON, Wis. In an age when microbial pathogens ... to tamp down infection, a team of Wisconsin scientists ... of curbing the bacteria that cause staph infections. , ... Chemical Society , a group led by University of ... interfere with the "quorum sensing" behavior of Staphylococcus ...
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2
... A combination of forest byproducts and crustacean shells may ... water, researchers from North Carolina State University have found. ... the major health risks posed by nuclear accidents is ... is chemically identical to non-radioactive iodide, the human body ...
... has been developed to carry out preimplantation genetic screening ... to the recipient uterus in the same in vitro ... The technique has been applied to the ... age, recurrent miscarriages or repeated implantation failures. ...
... NY) Just as inhaling cigarette smoke can cause lung ... Albert Einstein College of Medicine of Yeshiva University have ... of Health to clinically develop an inhaled therapy for lung ... and spreads. The grant recipients are Roman Perez-Soler, M.D., ...
Cached Biology News:Improvements in embryonic preimplantation genetic screening techniques 2NIH funds investigation of inhaled lung cancer treatment 2
... Sterile plating in just seconds , ... ethanol flaming, More uniform spreading and more ... dispenser bottle for spreading 100 plates or single-use ... easiest way to spread cells on multiple plates ...
... For laboratories working in a ... the only pipette calibration software that ... keeping within a framework that meets ... Pro is a secure solution that ...
... Testing Laboratory (RTL) can provide you ... years. ,,Microbial method development and validation ... the conditions of your GMP manufacturing ... products,,We offer a full spectrum of ...
... Research Scale (gram quantities of IgY) , After ... your Antigen), we segregate the appropriate number of ... 3 such eggs are collected (usually over a ... series. This involves a total of four injections ...
Biology Products: